Extensive-stage SCLC is an aggressive form of lung cancer with a dismal prognosis, and despite the advent of chemoimmunotherapy, survival outcomes remain poor, with limited second-line options available.Antibody-drug conjugates (ADCs) have emerged as an innovative therapeutic class in this context, leveraging tumor-associated antigens to deliver cytotoxic payloads with improved selectivity. ADCs targeting DLL3, TROP2, B7-H3, and SEZ6, together with earlier phase agents directed against CEACAM5, PTK7, and other emerging antigens, are advancing through clinical development and have demonstrated encouraging antitumor activity in second- and later-line settings.Primary and acquired resistance together with the limitations of current biomarkers for patient selection and response monitoring remain the major challenges to effective ADC implementation.This narrative review summarizes preliminary clinical data on ADCs, with particular emphasis on target biology, key molecular design features, potential central nervous system penetration, and the emerging safety profile. It also evaluates combination strategies with immune checkpoint and DNA-damage response inhibitors, the interplay and optimal sequencing with DLL3-directed T-cell engagers, and existing standards of care and future directions.

Monaca, F., Gomez-Randulfe, I., Torres-Jiménez, J., Agarwal, M., Liu, S. V., Paz-Ares, L., Califano, R., Antibody–Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond, <<JOURNAL OF THORACIC ONCOLOGY>>, 2026; 21 (9): N/A-N/A. [doi:10.1016/j.jtho.2026.103726] [https://hdl.handle.net/10807/350341]

Antibody–Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond

Monaca, Federico;
2026

Abstract

Extensive-stage SCLC is an aggressive form of lung cancer with a dismal prognosis, and despite the advent of chemoimmunotherapy, survival outcomes remain poor, with limited second-line options available.Antibody-drug conjugates (ADCs) have emerged as an innovative therapeutic class in this context, leveraging tumor-associated antigens to deliver cytotoxic payloads with improved selectivity. ADCs targeting DLL3, TROP2, B7-H3, and SEZ6, together with earlier phase agents directed against CEACAM5, PTK7, and other emerging antigens, are advancing through clinical development and have demonstrated encouraging antitumor activity in second- and later-line settings.Primary and acquired resistance together with the limitations of current biomarkers for patient selection and response monitoring remain the major challenges to effective ADC implementation.This narrative review summarizes preliminary clinical data on ADCs, with particular emphasis on target biology, key molecular design features, potential central nervous system penetration, and the emerging safety profile. It also evaluates combination strategies with immune checkpoint and DNA-damage response inhibitors, the interplay and optimal sequencing with DLL3-directed T-cell engagers, and existing standards of care and future directions.
2026
Inglese
Monaca, F., Gomez-Randulfe, I., Torres-Jiménez, J., Agarwal, M., Liu, S. V., Paz-Ares, L., Califano, R., Antibody–Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond, <<JOURNAL OF THORACIC ONCOLOGY>>, 2026; 21 (9): N/A-N/A. [doi:10.1016/j.jtho.2026.103726] [https://hdl.handle.net/10807/350341]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/350341
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 8
social impact